Boston Scientific Corporation (BSX) is scheduled to report third-quarter 2024 results on Oct. 23, before the opening bell.In the last reported quarter, the company’s earnings per share of 62 cents exceeded the Zacks Consensus Estimate by 6.9%. BSX’s bottom line beat estimates in each of the trailing four quarters. The company delivered a trailing four-quarter earnings surprise of 7.18%, on average.Q3 EstimatesThe Zacks Consensus Estimate for third-quarter total revenues is pegged at $4.03 billion, suggestin ...

Have you been paying attention to shares of Boston Scientific (BSX) ? Shares have been on the move with the stock up 4.8% over the past month. The stock hit a new 52-week high of $87.79 in the previous session. Boston Scientific has gained 51.4% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the 14.5% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our e ...

文章核心观点 - 波士顿科学公司(Boston Scientific)最近一个交易日的股价收于86.20美元,较前一个交易日下跌0.58% [1] - 公司股价表现落后于标普500指数,后者当日下跌0.21% [1] - 分析师预计公司2024年10月23日公布的第三季度财报,每股收益将同比增长16%至0.58美元,收入将同比增长14.36%至40.3亿美元 [1] - 公司全年的Zacks共识预测,每股收益和收入将分别同比增长17.07%和14.22% [2] - 分析师对公司业务健康状况和盈利能力持乐观态度,这反映在对公司业绩预测的上调 [2] 公司相关 - 公司最近一个月内股价上涨4.53%,超过医疗行业同期下跌3.28%,但低于标普500指数5.94%的涨幅 [1] - 公司目前市盈率为36.12倍,高于行业平均水平24.88倍 [3] - 公司目前市盈率增长比率(PEG)为2.87倍,高于行业平均水平1.92倍 [3] 行业相关 - 公司所属的医疗器械行业目前在250多个行业中排名第69位,位于前28% [4] - 研究显示,排名前50%的行业相比排名后50%的行业,业绩表现要好2倍 [4]

After a commendable run in the first nine months of 2024, the S&P 500 is poised to gain in the year’s final three months. The S&P 500 has risen 20.8% in the first three quarters of the year, and historically whenever the broader index has gained over 20%, it has, on average, risen 2.1% in the fourth quarter, per Dow Jones Market Data.In the October-December quarter, the S&P 500’s median return was as high as 4.1%, and the index gained more than 77% of the time, added Dow Jones Market Data.The Federal Reserv ...

Boston Scientific (BSX) ended the recent trading session at $84.49, demonstrating a +0.42% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of 0.01%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.08%.The medical device manufacturer's shares have seen an increase of 3.7% over the last month, surpassing the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21%.Investors will be eagerly watching for the perfor ...

Boston Scientific’s (BSX) growth is backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Consistent MedSurg market share gain is also highly encouraging. Meanwhile, headwinds such as currency movements raise concern for Boston Scientific.In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 63.3% compared with the industry’s 26.5% growth and the S&P 500 compos ...

-Company to also host virtual webcast with a cardiology business update-MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will ...

MedTech manufacturers, who were literally hankering for the easing of monetary policy following a prolonged period of challenging business scenarios, probably heaved a sigh of relief after September’s aggressive rate cut. The highly-anticipated 50-bps rate cut by the Fed, bringing the federal funds rate to a 4.75% to 5% target range, is considered a turning point in overcoming the ongoing challenges of a period of decline and decadence within the MedTech space.With a high probability of another half a perce ...

Boston Scientific Corporation (BSX) recently received the Pharmaceuticals and Medical Device Agency’s (“PMDA”) approval in Japan for its FARAPULSE Pulsed Field Ablation (“PFA”) System. The FARAPULSE PFA System is used for treating paroxysmal atrial fibrillation (AF).Boston Scientific expects to launch the FARAPULSE PFA System in Japan in the upcoming weeks to treat approximately 1 million people affected by AF.BSX’s Likely Stock Trend Following the NewsSubsequent to the announcement, shares of BSX moved nor ...

The most recent trading session ended with Boston Scientific (BSX) standing at $83.08, reflecting a -0.5% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.4%. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%.Coming into today, shares of the medical device manufacturer had gained 5.01% in the past month. In that same time, the Medical sector lost 2.27%, while the S&P 500 gained 1.71%.The investment communi ...